Skip to content
    NOVT
    Earnings call· Dec 2025(Q4 FY25)

    NOVANTA Q4 FY25 earnings call NOVT

    Feb 24, 2026 Source

    Executive summary

    Novanta Q4 FY25 — Strong Bookings and Organic Growth Return, AI Tailwinds Emerging

    Novanta delivered on its promise of returning to organic growth and double-digit profit growth in Q4 FY25, driven by broad-based bookings momentum and strong new product adoption. While manufacturing transfer costs temporarily impacted margins and cash flow, management expects these issues to resolve in H1 2026, setting the stage for mid-single-digit organic growth and significant capital deployment for M&A in the coming year, particularly in medical technologies and embedded software.

    Highlights

    5

    • Record Q4 revenue with 9% reported growth and 2% organic growth.

    • Bookings surged 25% YoY and 12% sequentially, with a book-to-bill of 1.11 across all businesses.

    • Adjusted EBITDA grew 17% YoY to $61 million and adjusted diluted EPS grew 20% YoY to $0.91.

    • New product revenue grew over 80% in Q4, reaching 24% of sales.

    • Ended Q4 with negative net debt of $121 million, a positive net cash position.

    Concerns

    3

    • Q4 gross margins (45.5%) and operating cash flow ($9 million) came in below expectations due to higher dual running costs from prioritizing customer deliveries over regional manufacturing transfers, impacting gross margin by over 100 bps.

    • Net working capital increased by 400 basis points as a percent of sales in Q4 due to higher inventory builds and temporary AR timing.

    • Full-year 2026 EPS guidance includes a $0.22-$0.24 headwind from equity fundraise dilution and a $0.14 impact from a one-time employee equity grant in H1 2026.

    Guidance & targets

    31
    CategoryTargetConfidence
    GAAP revenue
    $1030 million to $1050 million
    high materiality
    High
    Organic revenue growth
    4% to 6%
    high materiality
    High
    Organic revenue growth
    positive 1% to positive 3%
    medium materiality
    High
    Reported revenue growth
    positive 7% to positive 9%
    medium materiality
    High
    GAAP revenue
    $250 million to $255 million
    medium materiality
    High
    Organic revenue growth
    positive 5% to positive 7%
    medium materiality
    High
    Adjusted gross margin
    approximately 47%
    high materiality
    High
    R&D and SG&A expenses
    approximately $294 million to $298 million
    medium materiality
    Medium
    Depreciation expense
    approximately $17 million
    low materiality
    High
    Stock compensation expense
    nearly $38 million
    low materiality
    High
    Stock compensation expense
    approximately $12 million
    low materiality
    High
    Stock compensation expense
    approximately $11 million
    low materiality
    High
    Stock compensation expense
    approximately $8 million a quarter
    low materiality
    High
    Adjusted EBITDA
    $245 million and $250 million
    high materiality
    High
    Adjusted EBITDA
    $56 million to $58 million
    medium materiality
    High
    Interest expense, net of interest income
    roughly $8 million
    low materiality
    High
    Interest expense
    approximately $2 million
    low materiality
    High
    Non-GAAP tax rate
    around 21%
    low materiality
    High
    Non-GAAP tax rate
    between 19% and 20%
    low materiality
    High
    Diluted weighted average shares outstanding
    approximately 41 million shares
    medium materiality
    High
    Diluted earnings per share
    $3.50 and $3.65
    high materiality
    High
    Diluted earnings per share
    $0.75 to $0.80
    medium materiality
    High
    Operating cash flow
    approximately $145 million to $185 million
    high materiality
    Medium
    Cash flow conversion
    greater than 100% of GAAP net income
    medium materiality
    High
    Automation Enabling Technology segment growth
    low to mid-single-digit growth
    medium materiality
    High
    Medical Solutions segment growth
    high single-digit to low double-digit reported growth
    medium materiality
    High
    Advanced Surgery business revenue growth
    double-digit
    medium materiality
    High
    Robotics and Automation business growth
    high single-digit
    medium materiality
    High
    Precision Manufacturing business growth
    mid-single-digit
    medium materiality
    High
    Precision Medicine business sales
    roughly flat
    low materiality
    Medium
    Advanced Surgery business revenue
    approximately $400 million
    medium materiality
    Medium

    Segment performance

    6
    SegmentRevenueYoYQoQMargin
    Automation Enabling Technologies
    Better than expected revenue growth in Q4. Adjusted gross margins were up sequentially in Q4 but down year-over-year, driven by site regionalization dynamics. Expected to achieve low to mid-single-digit growth in Q1 FY26, an acceleration from Q4, based on building momentum in bookings and backlog.
    Book-to-bill: 1.16 (Q4 FY25)Bookings growth YoY: 33% (Q4 FY25)Full year sales growth: 2% (FY25)Full year bookings growth: 20% (FY25)Full year book-to-bill: 1.02 (FY25)New product revenue growth YoY: >80% (Q4 FY25)Full year new product revenue growth YoY: ~90% (FY25)Vitality Index: >20% (Q4 FY25)Vitality Index: high teens % (FY25)Customer design wins growth YoY: >30% (FY25)
    		—2%—49% adjusted gross margins (FY25)
    Medical Solutions
    Strong growth in Q4 driven by Advanced Surgery and the Keonn acquisition in Precision Medicine. Margin performance was impacted by manufacturing site dynamics. Expected to achieve high single-digit to low double-digit reported growth in Q1 FY26, with normal sequential decline due to seasonality but solid year-over-year growth.
    Book-to-bill: 1.07 (Q4 FY25)Bookings growth YoY: 17% (Q4 FY25)Full year sales growth: 5% (FY25)Full year bookings growth: 8% (FY25)Full year book-to-bill: 1.01 (FY25)New product sales growth YoY: ~80% (Q4 FY25)Vitality Index: ~28% (Q4 FY25)Full year new product sales growth YoY: >50% (FY25)Full year Vitality Index: 27% (FY25)
    		—16%—43% adjusted gross margins (Q4 FY25)
    Advanced Surgery
    Experienced strong growth in Q4, driven by patient procedural surgical growth rates and new product launches of second-generation insufflators. These growth dynamics are expected to continue into 2026 and beyond. Long-term, the business is on track to achieve approximately $400 million in revenue by 2030.
    		—15%——
    Precision Medicine
    Experienced sequential revenue growth in Q4. Year-over-year growth was largely driven by the Keonn acquisition and favorable comparables. The business continues to gradually digest life science equipment end market dynamics. Sales are expected to be roughly flat in 2026 with some shifts in demand.
    		—16%4%—
    Precision Manufacturing
    Saw 4 consecutive quarters of double-digit bookings growth and accelerating sequential revenue momentum in H2 2025. Customer destocking has subsided, and strong design wins are coming to speed in 2026. Expected to see mid-single-digit growth in 2026.
    		—-3%8%—
    Robotics and Automation
    Continues to see a sustainable growth outlook with three distinct AI-driven tailwinds: physical AI applications, recovering semiconductor wafer fab equipment market, and GPU drilling. Expected to achieve high single-digit growth in 2026.
    		—6%2%—

    Operational metrics

    34
    Non-GAAP adjusted gross profit
    $118 million
    Q4 FY25

    Compared to $112 million in Q4 FY24.

    Non-GAAP adjusted gross profit
    $452 million
    FY25

    Compared to $442 million in FY24.

    Adjusted gross margin
    45.5%down 150 bps YoY, down 100 bps sequentially
    Q4 FY25

    Came in below November guidance due to higher dual running costs from prioritizing customer deliveries over transfer timing.

    Adjusted gross margin
    46%down 50 bps YoY
    FY25

    Compared to 46.5% in FY24.

    R&D expenses
    $23 million
    Q4 FY25

    For Q4 FY25.

    R&D expenses
    $95 million
    FY25

    For FY25.

    SG&A expenses (non-GAAP)
    $46 million
    Q4 FY25

    Excluding certain adjustments.

    SG&A expenses (non-GAAP)
    $181 million
    FY25

    Excluding certain adjustments.

    Adjusted EBITDA
    $61 million17% YoY growth
    Q4 FY25

    Achieved strong growth.

    Non-GAAP tax rate
    20.5%
    Q4 FY25

    Versus 24% in Q4 FY24.

    Non-GAAP tax rate
    21%
    FY25

    Versus 20% in FY24. Increased year-over-year due to jurisdictional mix of pretax income.

    Non-GAAP adjusted EPS
    $0.9120% YoY growth
    Q4 FY25

    Achieved despite adding 2.7 million incremental shares from November equity fundraise.

    Non-GAAP adjusted EPS
    $3.297% YoY growth
    FY25

    For the full year.

    Net working capital
    400 basis point increase
    Q4 FY25

    Increase due to prioritizing customer deliveries over transfer timing, leading to elevated inventory.

    Gross debt
    $260 million
    year-end

    At year-end.

    Gross leverage ratio
    1.2x
    year-end

    At year-end.

    Cash and investments balance
    $381 million
    year-end

    Cash balance at year-end.

    Net debt
    negative $121 million
    year-end

    Resulting in a positive net cash position for the first time in over a decade.

    Net leverage ratio
    negative 0.5x
    year-end

    At year-end.

    Revolving credit facility paydown
    over $300 million
    Q4 FY25

    Used proceeds from November fundraise to pay down, giving near-term savings in interest expense.

    Amortizing notes added
    approximately $111 million
    Q4 FY25

    Added to balance sheet as part of November offering, partly offsetting revolver paydown.

    Stock repurchases
    $19 million
    Q4 FY25

    Repurchased company stock in Q4.

    Stock repurchases
    nearly $40 million
    FY25

    Repurchased shares for the full year.

    Medical end markets sales
    53%
    FY25

    Represented 53% of total sales.

    Advanced industrial markets sales
    47%
    FY25

    Represented 47% of total sales.

    Medical consumable sales
    15%strong double-digit rate
    FY25

    As a percent of total company sales, growing at a strong double-digit rate versus prior year due to high attachment rate in next generation insufflator product launches.

    New product sales growth
    over 80%YoY
    Q4 FY25

    Exceeding expectations.

    New product sales growth
    over 60%YoY
    FY25

    For the full year.

    Customer design wins growth
    up over 20%YoY
    FY25

    Company-wide design wins.

    Acquisition capacity
    nearly $1.5 billion
    current

    Total acquisition capacity, following $600 million fundraise.

    GPU drilling application revenue growth
    strong double-digit rate
    current

    For the application of air bearing spindles for drilling AI-driven GPU boards.

    EPS headwind from equity fundraise
    $0.22 to $0.24
    FY26

    Unfavorable impact included in FY26 guidance, partially offset by lower interest expense.

    EPS headwind from one-time employee equity grant
    $0.14
    H1 FY26

    Temporary unfavorable impact included in FY26 guidance, only impacts the first half of 2026.

    R&D and SG&A expenses as percent of sales
    30%
    Q1 FY26

    Higher than rest of the year due to aggressive deployment of AI tools and higher stock compensation expense from one-time grant.

    Industry KPIs

    9
    MetricValueDetails
    M a contribution$9 millionUSD
    Orders book to bill1.11
    Segment revenue growth2%%
    Design wins product cycle rampsup over 20%%
    Order visibility backlog policy—
    Recurring software services mix15%%
    Capacity expansion internal sourcing—
    End market revenue mix organic growth53%%
    Operating margin incremental leverage23.5%%

    Orderbook & backlog

    19
    Bookings growth25%Q4 FY25

    12% sequentially

    Year-over-year growth; company-wide.

    Bookings growth14%FY25

    Full year growth; company-wide.

    Book-to-bill1.11Q4 FY25

    Company-wide; all businesses had positive book-to-bill for the first time since 2022.

    Book-to-bill1.01FY25

    Company-wide.

    Book-to-bill1.16Q4 FY25

    Automation Enabling Technologies segment.

    Bookings growth33%Q4 FY25

    Year-over-year growth for Automation Enabling Technologies segment.

    Book-to-bill1.2Q4 FY25

    Precision Manufacturing business.

    Bookings growthnearly 50%Q4 FY25

    Growth for Precision Manufacturing business.

    Backlogabout $100 millionQ4 FY25

    For Precision Manufacturing business, approximately 2x its quarterly revenue.

    Book-to-bill1.13Q4 FY25

    Robotics and Automation business.

    Bookings growthclose to 25%Q4 FY25

    Growth for Robotics and Automation business.

    Backlogroughly 1.5xQ4 FY25

    For Robotics and Automation business, relative to actual quarterly revenue.

    Book-to-bill1.07Q4 FY25

    Medical Solutions segment.

    Bookings growth17%Q4 FY25

    Year-over-year growth for Medical Solutions segment.

    Book-to-bill1.12Q4 FY25

    Advanced Surgery business.

    Backlogroughly 2xQ4 FY25

    For Advanced Surgery business, relative to quarterly revenue.

    Book-to-bill1.01Q4 FY25

    Precision Medicine business.

    Bookings growth22%Q4 FY25

    Year-over-year growth for Precision Medicine business.

    Backlognearly 2xQ4 FY25

    For Precision Medicine business, relative to quarterly revenue.

    Product announcements

    3
    ProductTypeDetails
    Next-generation insufflatorlaunch
    Intelligent laser beam steering subsystemslaunch
    Content in warehouse robotics spacelaunch

    Deals & partnerships

    2
    KeonnAcquisition of a company specializing in intelligent RFID solutions and advanced machine vision technologies.

    The business has project-based revenue and a recurring revenue stream associated with software middleware for data control from RFID readers. This strategic element, particularly its applicability in the hospital environment, attracted Novanta.

    Unnamed business in SpainMinority investment in a business with frontline access to the hospital environment.very small

    Allows Novanta to beta test products in the hospital environment, understand market penetration, and navigate regulatory hurdles around data and patient privacy. The business is similar to Keonn.

    Capital programs

    1
    Regionalized manufacturing initiativeunderway

    Benefit: Solidify and expand preferred supplier status with leading OEMs globally, build manufacturing competence centers with better scale, stronger systems, and deeper talent with full in-region-for-region capability. Long-term benefits to profitability, cash flow, and resilience.

    Designed to help customers thrive in a deglobalizing world. In Q4 FY25, prioritizing customer deliveries over transfer timing created temporary higher dual running costs and elevated inventory. Cost structure adjusted in January. Expected to drive approximately 100 basis points of gross margin expansion in FY26.

    Risks & headwinds

    3
    Higher dual running costs and elevated inventory from regional manufacturing transfersQ4 FY25, expected to resolve by Q2 FY26

    More than a 100 basis point impact to gross margin; 400 basis point increase to net working capital as a percent of sales.

    Mitigation: Cost structure adjusted in January without disrupting deliveries or revenue momentum. Gross margins expected to step up sequentially in Q1, with transfers completed by end of Q2.

    Dilution from equity fundraiseFull year 2026

    $0.22 to $0.24 unfavorable impact to FY26 EPS.

    Mitigation: Management expects to deploy the raised capital towards acquisitions, which would generate income and offset the headwind.

    Temporary unfavorable impact from one-time 2025 all-employee equity grantFirst half of 2026 only

    $0.14 impact to H1 2026 EPS.

    What to watch in Q1 FY26

    5

    Regional manufacturing transfer completion and margin recovery

    Q1 2026, Q2 2026
    CurrentQ4 FY25 gross margin 45.5%, impacted by >100 bps from dual running costs.
    TargetGross margins step up sequentially in Q1, transfers completed by end of Q2.

    Why it matters

    Successful completion is key to achieving full-year gross margin expansion target of 100 bps and strong cash flow rebound.

    Gross margins are expected to step up sequentially in the first quarter and the transfer will be completed by the end of the second quarter. As a result, our full year 2026 gross margin expansion target of approximately 100 basis points of expansion versus 2025 is intact.

    Q&A highlights

    6

    What drove the sequential increase in AET bookings, which businesses/products, and what is the mix of longer lead time vs. book-and-ship?

    Management stated the bookings growth was broad-based across Robotics & Automation (precision robotics, recovering semi, GPU board drilling) and Precision Manufacturing (customer destocking subsided, strong design wins, new laser beam steering subsystems). Specific book-to-bill and backlog figures were provided for each business unit, indicating strong momentum and growing backlogs across the board.

    “Yes, Lee, it's pretty broad-based, right? We commented that all our businesses, so including also the Medical Solutions businesses had double-digit bookings growth and a positive book-to-bill for the first time since 2022.”

    asked by Lee Jagoda · answered by Matthijs Glastra

    2 min read6 chapters

    Detailed Narrative

    01

    Q4 Performance Highlights

    Novanta delivered record Q4 revenue with 9% reported growth and 2% organic growth, exceeding expectations. Bookings surged 25% year-over-year and 12% sequentially, achieving a book-to-bill of 1.11 across all businesses for the first time since 2022. New product revenue grew over 80% in Q4, contributing 24% to sales, demonstrating strong commercial excellence and innovation. Full-year revenue reached $981 million, the biggest year ever for the company.

    02

    Strategic Growth Pillars and Market Opportunity

    The company's long-term strategy focuses on winning in high-growth end markets with durable secular tailwinds, including AI-driven robotics and automation, minimally invasive and robotic surgery, digital manufacturing, and precision medicine. Novanta holds leading technology positions and established long-term collaborative partnerships with OEM customers. These growth platforms represent a $4 billion incremental market opportunity by 2030, with a strategic focus on expanding medical technologies, medical consumables, and embedded software.

    03

    Acquisition Strategy and Capacity

    Acquisitions are a key pillar for double-digit reported revenue growth and compounding cash flows. Novanta has built its largest acquisition pipeline, focusing on mid-to-larger opportunities in medical technologies, medical consumables, bioprocessing, and embedded software. Following a $600 million fundraise in November, the company now has nearly $1.5 billion in total acquisition capacity and expects to deploy meaningful capital in 2026, adhering to disciplined value creation metrics.

    04

    AI-Driven Tailwinds in Robotics and Automation

    The Robotics and Automation business benefits from three distinct AI-driven tailwinds: Novanta's technology leadership in physical AI applications for precision robotics (e.g., warehouse automation, humanoids), a recovering semiconductor wafer fab equipment market, and a unique position as the sole qualified supplier for drilling AI-driven GPU boards. This GPU board application is growing at a strong double-digit rate, directly benefiting from the ongoing build-out of AI compute infrastructure.

    05

    Manufacturing Regionalization and Margin/Cash Flow Impact

    A deliberate decision in Q4 to prioritize customer deliveries over the pace of regional manufacturing transfers led to higher dual running costs and elevated inventory, impacting gross margins by over 100 basis points and increasing net working capital by 400 basis points. Management adjusted the cost structure in January and expects gross margins to step up sequentially in Q1 2026, with transfers completed by Q2 2026, supporting a full-year 2026 gross margin expansion target of 100 basis points.

    06

    Financial Position and Capital Allocation

    Novanta ended Q4 with a positive net cash position, with net debt of negative $121 million, a first in over a decade. This was achieved by using fundraise proceeds to pay down over $300 million of its revolving credit facility. While M&A is the top capital allocation priority, the company repurchased $19 million of stock in Q4 and nearly $40 million for the full year 2025 under its approved program, demonstrating a balanced approach to capital deployment.

    AI-generated summary of the company’s earnings call. Not investment advice.